4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - No

被引：1
作者：
Goebel, Kerstin [1 ]
Wiendl, Heinz [1 ]
机构：
[1] Univ Munster, Inst Translat Neurol, Dept Neurol, Campus 1,Bldg A1, D-48149 Munster, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 11期
关键词：
MULTIPLE-SCLEROSIS; DALFAMPRIDINE; MECHANISM; CHANNELS;
D O I：
10.1177/1352458520924267
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1311 / 1312
页数：2
相关论文
共 10 条
  • [1] Potential therapeutic mechanism of K+ channel block for MS
    Baker, Mark D.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (04) : 270 - 280
  • [2] Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis
    Dunn, Jeffrey
    Blight, Andrew
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (07) : 1415 - 1423
  • [3] 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis
    Goebel, Kerstin
    Wedell, Jan-Hendrik
    Herrmann, Alexander M.
    Wachsmuth, Lydia
    Pankratz, Susann
    Bittner, Stefan
    Budde, Thomas
    Kleinschnitz, Christoph
    Faber, Cornelius
    Wiendl, Heinz
    Meuth, Sven G.
    [J]. EXPERIMENTAL NEUROLOGY, 2013, 248 : 62 - 71
  • [4] Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    Goodman, A. D.
    Cohen, J. A.
    Cross, A.
    Vollmer, T.
    Rizzo, M.
    Cohen, R.
    Marinucci, L.
    Blight, A. R.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 (03): : 357 - 368
  • [5] A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
    Goodman, Andrew D.
    Brown, Theodore R.
    Edwards, Keith R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Cohen, Ron
    Marinucci, Lawrence N.
    Blight, Andrew R.
    [J]. ANNALS OF NEUROLOGY, 2010, 68 (04) : 494 - 502
  • [6] Potassium channel blockers in multiple sclerosis:: Neuronal KV channels and effects of symptomatic treatment
    Judge, Susan I. V.
    Bever, Christopher T., Jr.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2006, 111 (01) : 224 - 259
  • [7] Ion Channels in Neurological Disorders
    Kumar, Pravir
    Kumar, Dhiraj
    Jha, Saurabh Kumar
    Jha, Niraj Kumar
    Ambasta, Rashmi K.
    [J]. ION CHANNELS AS THERAPEUTIC TARGETS, PT A, 2016, 103 : 97 - 136
  • [8] 4-Aminopyridine Induced Activity Rescues Hypoexcitable Motor Neurons from Amyotrophic Lateral Sclerosis Patient-Derived Induced Pluripotent Stem Cells
    Naujock, Maximilian
    Stanslowsky, Nancy
    Bufler, Sebastian
    Naumann, Marcel
    Reinhardt, Peter
    Sterneckert, Jared
    Kefalakes, Ekaterini
    Kassebaum, Carola
    Bursch, Franziska
    Lojewski, Xenia
    Storch, Alexander
    Frickenhaus, Marie
    Boeckers, Tobias M.
    Putz, Stefan
    Demestre, Maria
    Liebau, Stefan
    Klingenstein, Moritz
    Ludolph, Albert C.
    Dengler, Reinhard
    Kim, Kwang-Soo
    Hermann, Andreas
    Wegner, Florian
    Petri, Susanne
    [J]. STEM CELLS, 2016, 34 (06) : 1563 - 1575
  • [9] Long-term effects of dalfampridine in patients with multiple sclerosis
    Ruck, T.
    Bittner, S.
    Simon, O. J.
    Goebel, K.
    Wiendl, H.
    Schilling, M.
    Meuth, S. G.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 337 (1-2) : 18 - 24
  • [10] The Use of Aminopyridines in Neurological Disorders
    Sedehizadeh, Saam
    Keogh, Michael
    Maddison, Paul
    [J]. CLINICAL NEUROPHARMACOLOGY, 2012, 35 (04) : 191 - 200
1